ResourcesProfitability Of Infused Biologics For Hospitals And Physician Practices: Case Study Of Keytruda Resources / healnetwork1
ResourcesAssessing The Value Of Post-Approval Research For U.S. Policy Makers Resources / healnetwork1
ResourcesWhy Do We Hear More About High Drug Prices Than About Hospital Prices? Resources / healnetwork1
ResourcesFormulary-Related Insurance Denials of Single-Source Branded Drugs in the United States Resources / healnetwork1
ResourcesStretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program Resources / healnetwork1
Op-Ed, ResourcesOp-ed at The Well News: The 340B Windfall That Misses Patients Op-Ed, Resources / healnetwork1
ResourcesThe Forgotten Opportunity: Improving Traditional Medicare Operations Resources / healnetwork1
ResourcesWhen Safety-Net Programs Compete: Medicaid, 340B, And the Battle Over Drug Discounts Resources / healnetwork1
